<p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）在周三发布的一份报告中，摩根大通的股票分析师将其目标价格从 93.00 美元上调至 101.00 美元，MarketScreener 报道。该券商目前对这家药房运营商的股票给予 “增持” 评级。摩根大通的目标价格暗示该股票当前价格有 29.77% 的潜在上涨空间。</p>
<ul>
<li>CVS Health 因收入增长而上涨，股息保持强劲</li>
</ul>
<p>其他几位股票分析师最近也对该股票发表了评论。Wolfe Research 将 CVS Health 的目标价格从 85.00 美元上调至 100.00 美元，并在 12 月 8 日的研究报告中给予该公司 “跑赢大盘” 评级。Barclays 将 CVS Health 的目标价格从 87.00 美元上调至 93.00 美元，并在 12 月 10 日的研究报告中给予该公司 “增持” 评级。高盛集团将 CVS Health 的目标价格从 93.00 美元上调至 95.00 美元，并在 12 月 10 日的研究报告中给予该股票 “买入” 评级。摩根士丹利将 CVS Health 的目标价格从 89.00 美元上调至 93.00 美元，并在 12 月 10 日的研究报告中给予该股票 “增持” 评级。最后，瑞银集团在 12 月 10 日的报告中重申了对 CVS Health 的 “跑赢大盘” 评级。两位股票研究分析师给予该股票 “强烈买入” 评级，二十位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，CVS Health 目前的共识评级为 “适度买入”，共识目标价格为 94.67 美元。</p>
<p><strong>查看我们关于 CVS Health 的最新报告</strong></p>
<h2>CVS Health 价格表现</h2>
<ul>
<li>MarketBeat 周报 – 05/12 - 05/16</li>
</ul>
<p>CVS Health 的股票在周三开盘价为 77.83 美元。CVS Health 的 1 年低点为 43.56 美元，1 年高点为 85.15 美元。该公司的 50 日简单移动平均线为 79.05 美元，200 日简单移动平均线为 72.20 美元。该公司的流动比率为 0.83，速动比率为 0.63，债务与股本比率为 0.83。该股票的市值为 988 亿美元，市盈率为 206.18，PEG 比率为 0.79，贝塔值为 0.48。</p>
<p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）于 10 月 29 日发布了最新的财报。这家药房运营商报告本季度每股收益为 1.60 美元，超出分析师一致预期的 1.36 美元，超出幅度为 0.24 美元。CVS Health 的净利润率为 0.12%，股本回报率为 11.45%。该公司本季度的收入为 1028.7 亿美元，而分析师预期为 988.5 亿美元。去年同期，该公司的每股收益为 1.09 美元。该公司的收入同比增长 7.8%。CVS Health 已将其 2025 财年的指导目标设定为每股收益 6.550-6.650 美元。平均而言，卖方分析师预计 CVS Health 今年的每股收益为 5.89 美元。</p>
<h2>机构投资者对 CVS Health 的看法</h2>
<ul>
<li>现在是买入 Novo Nordisk 股票的好时机吗？</li>
</ul>
<p>大型投资者最近买入和卖出了该公司的股票。SOA Wealth Advisors LLC 在第三季度将其在 CVS Health 的持股增加了 36.9%。SOA Wealth Advisors LLC 目前拥有 486 股该药房运营商的股票，价值 37,000 美元，此前在该期间内又购买了 131 股。Alteri Wealth LLC 在第三季度将其在 CVS Health 的持股增加了 3.2%。Alteri Wealth LLC 目前拥有 4,195 股该药房运营商的股票，价值 316,000 美元，此前在该期间内又购买了 131 股。Holistic Financial Partners 在第三季度将其在 CVS Health 的持股增加了 4.1%。Holistic Financial Partners 目前拥有 3,397 股该药房运营商的股票，价值 256,000 美元，此前在上个季度又购买了 133 股。CYBER HORNET ETFs LLC 在第三季度将其在 CVS Health 的持股增加了 4.1%。CYBER HORNET ETFs LLC 目前拥有 3,442 股该药房运营商的股票，价值 259,000 美元，此前在该期间内又购买了 134 股。最后，Fayez Sarofim &amp; Co 在第三季度将其在 CVS Health 的持股增加了 2.1%。Fayez Sarofim &amp; Co 目前拥有 6,913 股该药房运营商的股票，价值 521,000 美元，此前在上个季度又购买了 140 股。80.66% 的股票目前由机构投资者持有。</p>
<h2>CVS Health 公司简介</h2>
<p>（获取免费报告）</p>
<p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房与消费者健康三个部门运营。医疗保险部门提供传统、自愿和消费者导向的健康保险产品及相关服务。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 CVS Health</li>
<li>市盈率计算：如何评估股票</li>
<li>三只下跌超过 60% 的科技股——哪一只值得购买？</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复</li>
<li>三只值得考虑的股息王</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 CVS Health 吗？</h2>
<p>在考虑 CVS Health 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 CVS Health 并不在名单上。</p>
<p>虽然 CVS Health 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西维斯

<p>摩根大通已将 CVS Health 的目标股价从 93.00 美元上调至 101.00 美元，维持 “增持” 评级，暗示潜在上涨幅度为 29.77%。其他分析师，包括 Wolfe Research 和巴克莱，也提高了他们的目标股价，CVS Health 获得了共识 “适度买入” 评级。该股开盘价为 77.83 美元，市值为 988 亿美元。CVS Health 报告了强劲的收益，年同比收入增长 7.8%</p>

<p>CVS Health (NYSE:CVS - Get Free Report) had its target price lifted by stock analysts at JPMorgan Chase &amp; Co. from $93.00 to $101.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has an &#34;overweight&#34; rating on the pharmacy operator's stock. JPMorgan Chase &amp; Co.'s price target would suggest a potential upside of 29.77% from the stock's current price.</p>
<div class="lb-trans"><p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）在周三发布的一份报告中，摩根大通的股票分析师将其目标价格从 93.00 美元上调至 101.00 美元，MarketScreener 报道。该券商目前对这家药房运营商的股票给予 “增持” 评级。摩根大通的目标价格暗示该股票当前价格有 29.77% 的潜在上涨空间。</p>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>CVS Health 因收入增长而上涨，股息保持强劲</li>
</ul>
</div><p>Several other equities analysts have also recently commented on the stock. Wolfe Research upped their target price on shares of CVS Health from $85.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research note on Monday, December 8th. Barclays increased their price objective on shares of CVS Health from $87.00 to $93.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. The Goldman Sachs Group increased their price target on shares of CVS Health from $93.00 to $95.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, December 10th. Morgan Stanley raised their price target on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Finally, UBS Group reissued an &#34;outperform&#34; rating on shares of CVS Health in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $94.67.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对该股票发表了评论。Wolfe Research 将 CVS Health 的目标价格从 85.00 美元上调至 100.00 美元，并在 12 月 8 日的研究报告中给予该公司 “跑赢大盘” 评级。Barclays 将 CVS Health 的目标价格从 87.00 美元上调至 93.00 美元，并在 12 月 10 日的研究报告中给予该公司 “增持” 评级。高盛集团将 CVS Health 的目标价格从 93.00 美元上调至 95.00 美元，并在 12 月 10 日的研究报告中给予该股票 “买入” 评级。摩根士丹利将 CVS Health 的目标价格从 89.00 美元上调至 93.00 美元，并在 12 月 10 日的研究报告中给予该股票 “增持” 评级。最后，瑞银集团在 12 月 10 日的报告中重申了对 CVS Health 的 “跑赢大盘” 评级。两位股票研究分析师给予该股票 “强烈买入” 评级，二十位给予 “买入” 评级，四位给予 “持有” 评级。根据 MarketBeat.com 的数据，CVS Health 目前的共识评级为 “适度买入”，共识目标价格为 94.67 美元。</p>
</div><p><strong>Check Out Our Latest Report on CVS Health</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CVS Health 的最新报告</strong></p>
</div><h2>CVS Health Price Performance</h2>
<div class="lb-trans"><h2>CVS Health 价格表现</h2>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 05/12 - 05/16</li>
</ul>
</div><p>Shares of CVS Health stock opened at $77.83 on Wednesday. CVS Health has a 1-year low of $43.56 and a 1-year high of $85.15. The firm has a fifty day simple moving average of $79.05 and a 200-day simple moving average of $72.20. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $98.80 billion, a price-to-earnings ratio of 206.18, a PEG ratio of 0.79 and a beta of 0.48.</p>
<div class="lb-trans"><p>CVS Health 的股票在周三开盘价为 77.83 美元。CVS Health 的 1 年低点为 43.56 美元，1 年高点为 85.15 美元。该公司的 50 日简单移动平均线为 79.05 美元，200 日简单移动平均线为 72.20 美元。该公司的流动比率为 0.83，速动比率为 0.63，债务与股本比率为 0.83。该股票的市值为 988 亿美元，市盈率为 206.18，PEG 比率为 0.79，贝塔值为 0.48。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts' consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm had revenue of $102.87 billion during the quarter, compared to analyst estimates of $98.85 billion. During the same quarter in the previous year, the business earned $1.09 EPS. The business's revenue was up 7.8% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, sell-side analysts expect that CVS Health will post 5.89 earnings per share for the current year.</p>
<div class="lb-trans"><p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）于 10 月 29 日发布了最新的财报。这家药房运营商报告本季度每股收益为 1.60 美元，超出分析师一致预期的 1.36 美元，超出幅度为 0.24 美元。CVS Health 的净利润率为 0.12%，股本回报率为 11.45%。该公司本季度的收入为 1028.7 亿美元，而分析师预期为 988.5 亿美元。去年同期，该公司的每股收益为 1.09 美元。该公司的收入同比增长 7.8%。CVS Health 已将其 2025 财年的指导目标设定为每股收益 6.550-6.650 美元。平均而言，卖方分析师预计 CVS Health 今年的每股收益为 5.89 美元。</p>
</div><h2>Institutional Investors Weigh In On CVS Health</h2>
<div class="lb-trans"><h2>机构投资者对 CVS Health 的看法</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是买入 Novo Nordisk 股票的好时机吗？</li>
</ul>
</div><p>Large investors have recently bought and sold shares of the business. SOA Wealth Advisors LLC. lifted its holdings in CVS Health by 36.9% in the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock worth $37,000 after buying an additional 131 shares during the period. Alteri Wealth LLC lifted its stake in shares of CVS Health by 3.2% in the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator's stock valued at $316,000 after purchasing an additional 131 shares during the period. Holistic Financial Partners boosted its position in shares of CVS Health by 4.1% during the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator's stock valued at $256,000 after purchasing an additional 133 shares in the last quarter. CYBER HORNET ETFs LLC grew its stake in CVS Health by 4.1% in the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator's stock worth $259,000 after purchasing an additional 134 shares during the period. Finally, Fayez Sarofim &amp; Co raised its holdings in CVS Health by 2.1% in the third quarter. Fayez Sarofim &amp; Co now owns 6,913 shares of the pharmacy operator's stock worth $521,000 after purchasing an additional 140 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。SOA Wealth Advisors LLC 在第三季度将其在 CVS Health 的持股增加了 36.9%。SOA Wealth Advisors LLC 目前拥有 486 股该药房运营商的股票，价值 37,000 美元，此前在该期间内又购买了 131 股。Alteri Wealth LLC 在第三季度将其在 CVS Health 的持股增加了 3.2%。Alteri Wealth LLC 目前拥有 4,195 股该药房运营商的股票，价值 316,000 美元，此前在该期间内又购买了 131 股。Holistic Financial Partners 在第三季度将其在 CVS Health 的持股增加了 4.1%。Holistic Financial Partners 目前拥有 3,397 股该药房运营商的股票，价值 256,000 美元，此前在上个季度又购买了 133 股。CYBER HORNET ETFs LLC 在第三季度将其在 CVS Health 的持股增加了 4.1%。CYBER HORNET ETFs LLC 目前拥有 3,442 股该药房运营商的股票，价值 259,000 美元，此前在该期间内又购买了 134 股。最后，Fayez Sarofim &amp; Co 在第三季度将其在 CVS Health 的持股增加了 2.1%。Fayez Sarofim &amp; Co 目前拥有 6,913 股该药房运营商的股票，价值 521,000 美元，此前在上个季度又购买了 140 股。80.66% 的股票目前由机构投资者持有。</p>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房与消费者健康三个部门运营。医疗保险部门提供传统、自愿和消费者导向的健康保险产品及相关服务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li>
<li>3 Dividend Kings To Consider</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 CVS Health</li>
<li>市盈率计算：如何评估股票</li>
<li>三只下跌超过 60% 的科技股——哪一只值得购买？</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复</li>
<li>三只值得考虑的股息王</li>
<li>AI 芯片离不开这两家被低估的科技巨头</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CVS Health 吗？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CVS Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 CVS Health 并不在名单上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CVS Health 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

摩根大通对西维斯健康（NYSE:CVS）股票价格发布了乐观的预测